10.43
-0.17 (-1.60%)
| Penutupan Terdahulu | 10.60 |
| Jumlah Dagangan | 377,116 |
| Harga / Buku (P/B) | 4.31 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.03 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.34% |
| Nisbah Semasa (MRQ) | 4.90 |
| Aliran Tunai Operasi (OCF TTM) | -28.53 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.17 M |
| Pulangan Atas Aset (ROA TTM) | -39.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -100.13% |
Sentimen Berita
AISkor Stockmoo
| Nilai 30% | -2.5 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info | |
| Masa 30% | -3.4 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Harga dan purata bergeraknya tersusun dalam aliran menurun. Purata bergerak utamanya sedang menurun. Hampir dengan purata bergerak yang menurun. Di bawah purata bergerak jangka panjang, jadi tidak dinilai positif. info | |
| Corak pembalikan menurun baru-baru ini: Engulfing menurun. info | |
| Di bawah garis aliran jangka sederhana. info | |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini bercampur atau neutral. info | |
| Wang Pintar 20% | -0.9 |
| Orang dalam membeli bersih baru-baru ini. Harga di bawah harga belian orang dalam. info | |
| Institusi bersih -1.83% daripada saham dalam pemfailan 13F terkini: 88 pemegang menambah, 79 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat -6.6% dari 31 Aug hingga 30 Oct 2026, 18.8 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Harga rendah berbanding purata 52 minggunya. Naik dalam tempoh 5 tahun. info | |
| Momentum jangka pendek meningkat. info | |
| Harga di antara sokongan dan rintangan. info | |
| Skor Akhir | -2.70 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Corvus Pharmaceuticals, Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CRVS | - | - | - | 4.31 |
| TRML | 1 B | - | - | 4.76 |
| CTMX | - | - | - | 1.56 |
| GANX | - | - | - | 4.54 |
| SRRK | - | - | - | 31.23 |
| IRON | - | - | - | 5.11 |
|
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.83% |
| % Dimiliki oleh Institusi | 48.27% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Adams Street Partners Llc | 30 Sep 2026 | 3,275,616 |
| Deep Track Capital, Lp | 30 Sep 2026 | 2,491,939 |
| Foresite Capital Management Vi Llc | 30 Sep 2026 | 1,831,233 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ARCARA JEFFREY | 11.19 | - | 4,500 | 50,360 |
| Jumlah Keseluruhan Kuantiti Bersih | 4,500 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 50,360 | |||
| Purata Pembelian Keseluruhan ($) | 11.19 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ARCARA JEFFREY | Pegawai | 13 Nov 2026 | Beli (+) | 1,003 | 10.64 | 10,672 |
| ARCARA JEFFREY | Pegawai | 12 Nov 2026 | Beli (+) | 497 | 10.62 | 5,278 |
| ARCARA JEFFREY | Pegawai | 11 Nov 2026 | Beli (+) | 3,000 | 11.47 | 34,410 |
Institusi
Pemilikan institusi: 86.31%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 88 | 6,554,089 |
| Berkurang | 79 | 8,031,042 |
| Baharu | 29 | 2,064,545 |
| Dijual habis | 18 | 2,124,893 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 17,759,451 | 18.8 |
| 15 Oct 2026 | 17,967,756 | 14.9 |
| 30 Sep 2026 | 17,797,751 | 13.3 |
| 15 Sep 2026 | 17,180,341 | 18.2 |
| 31 Aug 2026 | 19,017,840 | 29.6 |
| 14 Aug 2026 | 19,127,098 | 22.5 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 09 Nov 2026 | Yahoo Finance |
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026… |
| 06 Nov 2026 | Yahoo Finance |
Corvus (CRVS) Q3 2026 Earnings Call Transcript
Soquelitinib's expanding pipeline spans lymphoma, eczema, skin disease and asthma. |
| 06 Nov 2026 | Yahoo Finance |
Corvus Pharmaceuticals Inc (CRVS) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Key ...
Corvus Pharmaceuticals Inc (CRVS) reported a $20.3 million net loss but holds $202.9 million in cash to fund operations into Q2 2028, with pivotal socolitinib data readouts expected through 2027… |
| 06 Nov 2026 | Yahoo Finance |
Corvus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Moby summary of Corvus Pharmaceuticals, Inc.'s Q3 2026 earnings call… |
| 05 Nov 2026 | Yahoo Finance |
What Corvus Pharmaceuticals (CRVS) Said on Its Q3 Earnings Call
Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider third-quarter loss as spending on clinical trials increased, while executives outlined a series of 2027 milestones for its lead experimental drug, soquelitinib. The company reported a net loss of $20.3 million for the third quarter of 2026, comp… |
| 05 Nov 2026 | Yahoo Finance |
Corvus: Q3 Earnings Snapshot
(AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Corvus Pharmaceuticals Inc. |
| 05 Nov 2026 | Yahoo Finance |
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Angel Pharmaceuticals completes enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data anticipated in March 2027 Phase 1b… |
| 04 Nov 2026 | Yahoo Finance |
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Safety profile consistent with results from soquelitinib T cell lymphoma and atopic… |
| 29 Oct 2026 | Yahoo Finance |
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on… |
| 30 Sep 2026 | Yahoo Finance |
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Clinical trial designed to demonstrate proof-of-concept for soquelitinib in the treatment of hidradenitis suppurativa and evaluate its effects on Th17 biologySOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage… |
| 25 Sep 2026 | Yahoo Finance |
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?
Corvus Pharmaceuticals (CRVS) has drawn fresh attention after recent trading left the biotech down about 19% over the past month and 13% over the past 3 months from a US$11.80 close. That recent slide sits against a much stronger ride for Corvus Pharmaceuticals, with the share price return still up… |
| 03 Sep 2026 | Yahoo Finance |
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat… |
| 27 Aug 2026 | Yahoo Finance |
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment Highlights… |
| Papar semua | ||
Isyarat Terkini corak lilin dan silang EMA
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |